BACKGROUND AND OBJECTIVES: Restless legs syndrome (RLS) and sleep disturbances are common among in-center hemodialysis patients and are associated with increased morbidity/mortality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The FREEDOM study is an ongoing prospective cohort study investigating the benefits of home short daily hemodialysis (SDHD) (6 times/week). In this interim report, we examine the long-term effect of SDHD on the prevalence and severity of RLS, as measured by the International Restless Legs Syndrome (IRLS) Study Group rating scale, and sleep disturbances, as measured by the Medical Outcomes Study sleep survey. RESULTS: 235 participants were included in this report (intention-to-treat cohort), of which 127 completed the 12-month follow-up (per-protocol cohort). Mean age was 52 years, 55% had an arteriovenous fistula, and 40% suffered from RLS. In the per-protocol analysis, among patients with RLS, the mean IRLS score improved significantly at month 12, after adjustment for use of RLS-related medications (18 versus 11). Among patients with moderate-to-severe RLS (IRLS score ≥15), there was an even greater improvement in the IRLS score (23 versus 13). The intention-to-treat analysis yielded similar results. Over 12 months, there was decline in the percentage of patients reporting RLS (35% versus 26%) and those reporting moderate-to-severe RLS (59% versus 43%). There was a similar and sustained 12-month improvement in several scales of the sleep survey, after adjustment for presence of RLS and use of anxiolytics and hypnotics. CONCLUSIONS: Home SDHD is associated with long-term improvement in the prevalence and severity of RLS and sleep disturbances.
BACKGROUND AND OBJECTIVES:Restless legs syndrome (RLS) and sleep disturbances are common among in-center hemodialysis patients and are associated with increased morbidity/mortality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The FREEDOM study is an ongoing prospective cohort study investigating the benefits of home short daily hemodialysis (SDHD) (6 times/week). In this interim report, we examine the long-term effect of SDHD on the prevalence and severity of RLS, as measured by the International Restless Legs Syndrome (IRLS) Study Group rating scale, and sleep disturbances, as measured by the Medical Outcomes Study sleep survey. RESULTS: 235 participants were included in this report (intention-to-treat cohort), of which 127 completed the 12-month follow-up (per-protocol cohort). Mean age was 52 years, 55% had an arteriovenous fistula, and 40% suffered from RLS. In the per-protocol analysis, among patients with RLS, the mean IRLS score improved significantly at month 12, after adjustment for use of RLS-related medications (18 versus 11). Among patients with moderate-to-severe RLS (IRLS score ≥15), there was an even greater improvement in the IRLS score (23 versus 13). The intention-to-treat analysis yielded similar results. Over 12 months, there was decline in the percentage of patients reporting RLS (35% versus 26%) and those reporting moderate-to-severe RLS (59% versus 43%). There was a similar and sustained 12-month improvement in several scales of the sleep survey, after adjustment for presence of RLS and use of anxiolytics and hypnotics. CONCLUSIONS: Home SDHD is associated with long-term improvement in the prevalence and severity of RLS and sleep disturbances.
Authors: Linda Abetz; Robert Arbuckle; Richard P Allen; Diego Garcia-Borreguero; Wayne Hening; Arthur S Walters; Elena Mavraki; Jeffrey M Kirsch Journal: Sleep Med Date: 2006-05-19 Impact factor: 3.492
Authors: Bruce F Culleton; Michael Walsh; Scott W Klarenbach; Garth Mortis; Narine Scott-Douglas; Robert R Quinn; Marcello Tonelli; Sarah Donnelly; Matthias G Friedrich; Andreas Kumar; Houman Mahallati; Brenda R Hemmelgarn; Braden J Manns Journal: JAMA Date: 2007-09-19 Impact factor: 56.272
Authors: Jeffrey T Reynolds; Peter Homel; Lisa Cantey; Ellen Evans; Pamela Harding; Frank Gotch; Diane Wuerth; Susan Finkelstein; Nathan Levin; Alan Kliger; David B Simon; Fredric O Finkelstein Journal: Blood Purif Date: 2004-06-21 Impact factor: 2.614
Authors: Bertrand L Jaber; Fredric O Finkelstein; Joel D Glickman; Alan R Hull; Michael A Kraus; John K Leypoldt; Jiannong Liu; David Gilbertson; James McCarthy; Brent W Miller; John Moran; Allan J Collins Journal: Am J Kidney Dis Date: 2008-09-27 Impact factor: 8.860
Authors: Stacey J Elder; Ronald L Pisoni; Tadao Akizawa; Rachel Fissell; Vittorio E Andreucci; Shunichi Fukuhara; Kiyoshi Kurokawa; Hugh C Rayner; Anna L Furniss; Friedrich K Port; Rajiv Saran Journal: Nephrol Dial Transplant Date: 2007-10-01 Impact factor: 5.992
Authors: Eric D Weinhandl; Jiannong Liu; David T Gilbertson; Thomas J Arneson; Allan J Collins Journal: J Am Soc Nephrol Date: 2012-02-23 Impact factor: 10.121
Authors: Nikhil Shah; Frances Reintjes; Mark Courtney; Scott W Klarenbach; Feng Ye; Kara Schick-Makaroff; Kailash Jindal; Robert P Pauly Journal: Clin J Am Soc Nephrol Date: 2017-07-24 Impact factor: 8.237
Authors: Bessie A Young; Christopher Chan; Christopher Blagg; Robert Lockridge; Thomas Golper; Fred Finkelstein; Rachel Shaffer; Rajnish Mehrotra Journal: Clin J Am Soc Nephrol Date: 2012-10-04 Impact factor: 8.237
Authors: Fredric O Finkelstein; Kelli L Arsenault; Ana Taveras; Kwabena Awuah; Susan H Finkelstein Journal: Nat Rev Nephrol Date: 2012-10-23 Impact factor: 28.314
Authors: Mark L Unruh; Brett Larive; Paul W Eggers; Amit X Garg; Jennifer J Gassman; Fredric O Finkelstein; Paul L Kimmel; Glenn M Chertow Journal: Nephrol Dial Transplant Date: 2016-04-15 Impact factor: 5.992
Authors: Scott Klarenbach; Marcello Tonelli; Robert Pauly; Michael Walsh; Bruce Culleton; Helen So; Brenda Hemmelgarn; Braden Manns Journal: J Am Soc Nephrol Date: 2013-11-14 Impact factor: 10.121